Research Repository

See what's under the surface


Citrullinated α-enolase is an effective target for anti-cancer immunity (2017)
Journal Article
Cook, K., Daniels, I., Symonds, P., Pitt, T., Gijon, M., Xue, W., …Brentville, V. A. (2018). Citrullinated α-enolase is an effective target for anti-cancer immunity. OncoImmunology, 7(2), doi:10.1080/2162402X.2017.1390642. ISSN 2162-4011

Targeting post-translationally modified epitopes may provide a new strategy for generating tumor specific immune responses. Citrullination is the post-translational modification of arginine to citrulline catalyzed by peptidylarginine deaminase (PAD)... Read More

High mobility group protein B1 is a predictor of poor survival in ovarian cancer (2017)
Journal Article
Machado, L. R., Moseley, P. M., Moss, R., Deen, S., Nolan, C. C., Spendlove, I., …Durrant, L. (2017). High mobility group protein B1 is a predictor of poor survival in ovarian cancer. Oncotarget, doi:10.18632/oncotarget.20538. ISSN 1949-2553

High-mobility group protein B1 (HMGB1) has been implicated in numerous tumour types where expression regulates tumour cell growth and survival. We hypothesised that high HMGB1 expression in ovarian tumours would predict poor patient survival. Using... Read More

Cancer cell associated glycans as targets for immunotherapy (2015)
Journal Article
Vankemmelbeke, M., Chua, J. X., & Durrant, L. (2016). Cancer cell associated glycans as targets for immunotherapy. 00 Journal not listed, 5(1), doi:10.1080/2162402X.2015.1061177

Therapeutic anti-glycan antibodies for cancer treatment are limited, in spite of the differential glycophenotype of cancer cells and associated biology. We have generated anti-Le glycan antibodies with clinical potential and multifaceted functionalit... Read More

Monoclonal antibodies targeting LecLex-related glycans with potent antitumor activity (2015)
Journal Article
Chua, J., Vankemmelbeke, M., McIntosh, R. S., Clarke, P. A., Moss, R., Parsons, T., …Durrant, L. (2015). Monoclonal antibodies targeting LecLex-related glycans with potent antitumor activity. Clinical Cancer Research, 21(13), 2963–2974. doi:10.1158/1078-0432.CCR-14-3030

Purpose: To produce antitumor monoclonal antibodies (mAbs) targeting glycans as they are aberrantly expressed in tumors and are coaccessory molecules for key survival pathways. Experimental Design: Two mAbs (FG88.2 and FG88.7) recognizing novel tu... Read More

The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis (2014)
Journal Article
Ullenhag, G. J., Al-Attar, A., Mukherjee, A., Green, A. R., Ellis, I. O., & Durrant, L. G. (2015). The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis. Journal of Cancer Research and Clinical Oncology, 141(3), 505-514. doi:10.1007/s00432-014-1822-0

Background Breast cancer is the most common cancer in women. The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway transmits apoptotic signals. Novel anticancer agents that activate this system are in clinical development, in... Read More

Wavelet feature extraction and genetic algorithm for biomarker detection in colorectal cancer data (2013)
Journal Article
Liu, Y., Aickelin, U., Feyereisl, J., & Durrant, L. G. (2013). Wavelet feature extraction and genetic algorithm for biomarker detection in colorectal cancer data. Knowledge-Based Systems, 37, doi:10.1016/j.knosys.2012.09.011. ISSN 0950-7051

Biomarkers which predict patient’s survival can play an important role in medical diagnosis and treatment. How to select the significant biomarkers from hundreds of protein markers is a key step in survival analysis. In this paper a novel method is... Read More

Total loss of MHC class I is an independent indicator of good prognosis in breast cancer (2005)
Journal Article
Madjd, Z., Spendlove, I., Pinder, S. E., Ellis, I. O., & Durrant, L. G. (2005). Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. International Journal of Cancer, 117(2), doi:10.1002/ijc.21163. ISSN 0020-7136

Tumours can be recognised by CTL and NK cells. CTL recognition depends on expression of MHC Class I loaded with peptides from tumour antigens. In contrast, loss of MHC Class I results in NK activation. In our study a large set of samples from patient... Read More

Biomarker clustering of colorectal cancer data to complement clinical classification
Conference Proceeding
Roadknight, C., Aickelin, U., Ladas, A., Soria, D., Scholefield, J., & Durrant, L. Biomarker clustering of colorectal cancer data to complement clinical classification

In this paper, we describe a dataset relating to cellular and physical conditions of patients who are operated upon to remove colorectal tumours. This data provides a unique insight into immunological status at the point of tumour removal, tumour... Read More

Supervised learning and anti-learning of colorectal cancer classes and survival rates from cellular biology parameters
Conference Proceeding
Roadknight, C., Aickelin, U., Qiu, G., Scholefield, J., & Durrant, L. Supervised learning and anti-learning of colorectal cancer classes and survival rates from cellular biology parameters

In this paper, we describe a dataset relating to cellular and physical conditions of patients who are operated upon to remove colorectal tumours. This data provides a unique insight into immunological status at the point of tumour removal,tumour cl... Read More

An ensemble of machine learning and anti-learning methods for predicting tumour patient survival rates
Conference Proceeding
Roadknight, C., Suryanarayanan, D., Aickelin, U., Scholefield, J., & Durrant, L. (in press). An ensemble of machine learning and anti-learning methods for predicting tumour patient survival rates

This paper primarily addresses a dataset relating to cellular, chemical and physical conditions of patients gathered at the time they are operated upon to remove colorectal tumours. This data provides a unique insight into the biochemical and immunol... Read More